# A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors

> **NCT06390774** · PHASE1 · RECRUITING · sponsor: **Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.** · enrollment: 180 (estimated)

## Conditions studied

- Locally Advanced, Recurrent or Metastatic Malignancies

## Interventions

- **DRUG:** SSGJ-705

## Key facts

- **NCT ID:** NCT06390774
- **Lead sponsor:** Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-30
- **Primary completion:** 2026-12
- **Final completion:** 2027-02
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2024-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06390774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06390774, "A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06390774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*